Linebacker-1联合放疗在小鼠肺癌模型中的协同效应
本研究在A549、HT29及LLC1细胞系和小鼠Lewis肺癌皮下模型中评估杨梅素衍生物Linebacker-1(LB1)的抗癌与放射增敏作用。LB1在体外对A549和HT29有抗肿瘤效应,在体内与单次8 Gy图像引导放疗(IGRT)联用可缩小肿瘤体积并延长生存,加用抗PD1抗体进一步改善生存率。
要点
- LB1在A549和HT29细胞系中显示抗肿瘤效应(P < .001)。
- LB1联合单次8 Gy IGRT缩小小鼠肿瘤体积(P < .01)并延长生存(P < .001)。
- LB1联合抗PD1或IGRT+抗PD1进一步增加生存率(P < .05)。
核心结论
- LB1在肺癌模型中增强放疗的抗肿瘤效果,抗PD1治疗可进一步增强该效果。
研究设计与样本
- 体外研究使用人A549、HT29及小鼠LLC1癌细胞系。
- 在野生型C57/BL6小鼠单侧皮下接种LLC1细胞建立同种移植肺癌模型。
- 使用小动物辐射研究平台对肿瘤实施图像引导放疗(IGRT)。
主要发现
- LB1在体外诱导A549(P < .001)和HT29(P < .001)腺癌细胞系的抗肿瘤效应。
- 在小鼠肺癌模型中,单次8 Gy IGRT显著缩小肿瘤体积(P < .01)并提高生存百分比和延长生存时间(P < .001)。
- LB1联合抗PD1抗体或联合IGRT+抗PD1进一步增加生存百分比(分别为P < .05和P < .05)。
- 联合治疗未引起小鼠体重或体况评分的显著变化。
关键数值与推荐
- 单次8 Gy IGRT用于小鼠肺癌模型的放疗方案。
- LB1与抗PD1抗体或IGRT+抗PD1联合可进一步改善生存率(P < .05)。
临床怎么用
- LB1作为潜在放射增敏剂,与放疗及免疫检查点抑制剂联合可能增强肺癌治疗效果。
- 目前仅为临床前数据,需进一步在原位肺癌模型等研究中验证后方可考虑临床转化。
局限性
- 研究为小鼠皮下肺癌模型,非原位模型。
- 作者指出需进一步开展原位肺癌模型的体内研究以提供稳健的临床前数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Myricetin is a small-molecular-weight U.S. Food and Drug Administration-recognized dietary supplement showing efficient anticancer effects. The recent development of myricetin derivative Linebacker-1 (LB1), which changes a hydroxyl group on the B ring to a chlorine atom, exhibits DNA-binding ability by interacting with the minor grooves of DNA and may also act as an antitumor drug. This study demonstrates the anticancer effect and radiosensitization of LB1 in a lung cancer model. METHODS AND MATERIALS: In vitro studies were performed in human A549 (American Type Culture Collection [ATCC]) and HT29 (ATCC), and in murine Lewis lung carcinoma (LLC1) (ATCC) cancer cell lines. A syngeneic murine model of lung adenocarcinoma was generated subcutaneously in 1 flank of wild (+/+) C57/BL6 background mice using the LLC1 cell line. Image guided radiation therapy (IGRT) targeting the tumor was administered with a small animal radiation research platform. RESULTS: Our in vitro study observations demonstrate that LB1 induces an antineoplastic effect in human lung A549 (P < .001) and colon HT29 (P < .001) adenocarcinoma cell lines. In the murine lung cancer model, we further demonstrate that a single dose of 8 Gy IGRT substantially enhances treatment response by reducing tumor volume (P < .01) and increasing survival percent and duration (P < .001). In addition, adding LB1 with a checkpoint inhibitor (antibody to programmed death-1 [anti-PD1]) or with IGRT+ anti-PD1 further increases the survival percentage (P < .05, P < .05, respectively), with no significant change in mouse body weight or body score. CONCLUSIONS: LB1 demonstrates enhancement of the antitumor effect of radiation in a lung cancer model, whereas anti-PD1 treatment further enhances the effect. The results provide impetus for further studies, including in vivo studies in orthotopic lung cancer models, to provide robust preclinical data for potential future application of LB1 as a radiosensitizer in the clinic.
引用
- Yasmin-Karim S, Richards G, Makrigiorgos GM, et al. Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model. Adv Radiat Oncol. 2026. PMID: 42254817. doi:10.1016/j.adro.2026.102051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。